Cohance lifesciences Limited has responded to BSE's inquiry regarding the recent surge in trading volume of its shares, confirming that the movement is purely market-driven with no underlying material developments.

Regulatory Compliance Confirmation

In a filing dated April 13, 2026, the company addressed BSE's email seeking clarification on the increased volume of shares traded across exchanges. The pharmaceutical company provided comprehensive assurance regarding its compliance with disclosure requirements.

No Material Information Pending

Cohance Lifesciences explicitly confirmed that there is no pending information or announcement required to be disclosed under Regulation 30 of the SEBI Listing Regulations that could impact the price or volume behavior of the company's scrip. The management emphasized that the volume movement is attributable to prevailing market conditions rather than any specific corporate developments.

Disclosure Practices

The company reaffirmed its commitment to regulatory compliance, stating that it has been regularly notifying all Unpublished Price Sensitive Information (UPSI) as required under Regulation 30 and other applicable provisions of the SEBI Listing Regulations. This systematic approach to disclosure ensures market transparency and investor protection.

Corporate Structure

The filing was signed by Sisir K. Mishra, Company Secretary & Compliance Officer, representing Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited. The company maintains its corporate office in Hyderabad and registered office in Mumbai, continuing its operations in the pharmaceutical sector.

Cohance lifesciences Limited has submitted its quarterly regulatory certificate to stock exchanges, fulfilling mandatory compliance requirements under SEBI depositories regulations. The pharmaceutical company filed the certificate on April 02, 2026, covering the quarter ended March 31, 2026.

Regulatory Filing Details

The company submitted the certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 to both major stock exchanges where its shares are listed. Himanshu Agarwal, Whole-time Director and Chief Financial Officer, signed the submission on behalf of the company.

Stock Exchange Submissions

The regulatory certificate was filed with both BSE Limited and National Stock Exchange of India Limited, confirming the company's adherence to listing compliance requirements.

Registrar Confirmation

KFin Technologies Limited, acting as the company's Registrar and Share Transfer Agent, issued confirmation certificates to both depositories. C Shobha Anand, Vice President at KFin Technologies, certified that all details of securities dematerialized and rematerialized during the quarter have been furnished to stock exchanges as required.

The filing represents routine quarterly compliance by Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited, ensuring transparency in securities transactions and maintaining regulatory adherence for its listed shares.